Search results for " Combination"

showing 10 items of 923 documents

Topical Voriconazole as Supplemental Treatment for Acanthamoeba Keratitis

2020

Purpose Voriconazole was shown to inhibit ergosterol synthesis in various acanthamoeba species. The purpose of this study was to evaluate the clinical outcome of treatment with supplemental topical voriconazole in patients with acanthamoeba keratitis (AK). Methods All patients who had been treated for AK with voriconazole 1% drops in conjunction with topical first-line antiacanthamoeba therapy composed of polyhexamethylene biguanide (PHMB) 0.02% and propamidine isethionate 0.1% (Brolene) between November 2014 and August 2017 at the Department of Ophthalmology, University Medical Center Mainz, were included. The main outcomes were treatment failure and recurrence rate. Secondary outcomes wer…

AdultMalemedicine.medical_specialtyAntifungal AgentsVisual acuitymedicine.drug_classAntiprotozoal AgentsVisual AcuityAcanthamoebaCorneaYoung Adult03 medical and health sciences0302 clinical medicinePharmacotherapymedicineAnimalsHumansIn patientEye Infections ParasiticAgedRetrospective StudiesAged 80 and overVoriconazoleDose-Response Relationship Drugbusiness.industryBiguanideRetrospective cohort studyMiddle AgedEye infectionmedicine.diseaseDermatologyBenzamidinesOphthalmologyAcanthamoeba KeratitisAcanthamoeba keratitis030221 ophthalmology & optometryDrug Therapy CombinationFemaleVoriconazoleOphthalmic Solutionsmedicine.symptombusiness030217 neurology & neurosurgeryFollow-Up Studiesmedicine.drugCornea
researchProduct

Factors related to the impact of antihypertensive treatment in antioxidant activities and oxidative stress by-products in human hypertension

2004

The objective was to study factors related to the changes induced by antihypertensive treatment on oxidative status, antioxidant activities, and reactive oxygen species by-products in whole blood and mononuclear peripheral cells. Eighty-nine hypertensive patients (mean age 46 years, 46 men, average 24-h blood pressure 139/88 mm Hg, body mass index 29) were included. After 3 months of nonrandomized allocation to antihypertensive treatment (20 nonpharmacologic, 36 beta-blockers, 33 angiotensin receptor blocker), oxidized/reduced glutathione ratio and malondialdehyde were significantly reduced, and the activity of superoxide dismutase, catalase, and glutathione peroxidase was significantly inc…

AdultMalemedicine.medical_specialtyAntioxidantmedicine.medical_treatmentAngiotensin-Converting Enzyme Inhibitorsmedicine.disease_causeBenzoatesAntioxidantsSuperoxide dismutasechemistry.chemical_compoundInternal medicineInternal MedicinemedicineHumansTelmisartanAntihypertensive AgentsWhole bloodchemistry.chemical_classificationReactive oxygen speciesbiologybusiness.industryGlutathione peroxidaseGlutathioneMiddle AgedMalondialdehydeOxidative StressHydrochlorothiazideTreatment OutcomeEndocrinologyAtenololchemistryHypertensionbiology.proteinBenzimidazolesDrug Therapy CombinationFemalebusinessOxidative stressDNA DamageAmerican Journal of Hypertension
researchProduct

Five years experience on 3,4-diaminopyridine phosphate in Lambert-Eaton syndrome: Case reports

2017

Abstract Rationale: To report our experience on 7 patients (4 males and 3 females), affected by nonparaneoplastic Lambert–Eaton myasthenic syndrome, treated with 3,4-diaminopyridine phosphate (3,4-DAPP) either alone or in combination with other immunosuppressants or steroids. Patient concerns: Patients have been evaluated at specific timepoints (ie, baseline and last 5 year follow-up), with neurological examination, autoantibodies against presynaptic voltage-gated Cav2.1 (P/Q type) calcium ion channel (VGCC) dosage, neurophysiological evaluation focusing on the increased amplitude of the compound muscle action potential (cMAP) after maximum voluntary effort, quantitative myasthenia gravis (…

AdultMalemedicine.medical_specialtyAzathioprineNeurological examination030204 cardiovascular system & hematologySeverity of Illness Index5300nonparaneoplastic-Lambert–Eaton myasthenic syndrome03 medical and health sciences0302 clinical medicinePrednisoneInternal medicineSeverity of illnessActivities of Daily LivingAzathioprinemedicineHumansMuscle StrengthClinical Case Report4-AminopyridineAdverse effect34-diaminopyridine phosphate; nonparaneoplastic-Lambert-Eaton myasthenic syndrome; 4-Aminopyridine; Activities of Daily Living; Adult; Azathioprine; Drug Therapy Combination; Female; Humans; Immunosuppressive Agents; Lambert-Eaton Myasthenic Syndrome; Male; Middle Aged; Muscle Strength; Prednisone; Severity of Illness Index; Treatment Outcome; Medicine (all)medicine.diagnostic_testbusiness.industry34-diaminopyridine phosphateGeneral MedicineMiddle Agedmedicine.diseaseMyasthenia gravisLambert-Eaton Myasthenic SyndromeTreatment OutcomeConcomitantPrednisoneDrug Therapy CombinationFemaleAmifampridinebusinessLambert-Eaton myasthenic syndrome030217 neurology & neurosurgeryImmunosuppressive Agentsmedicine.drugResearch Article
researchProduct

Clinical and psychopathological features associated with treatment-emergent mania in bipolar-II depressed outpatients exposed to antidepressants

2018

Abstract Background Treatment-emergent affective switch (TEAS), including treatment-emergent mania (TEM), carry significant burden in the clinical management of bipolar depression, whereas the use of antidepressants raises both efficacy, safety and tolerability concerns. The present study assesses the prevalence and clinical correlates of TEM in selected sample of Bipolar Disorder (BD) Type-II (BD-II) acute depression outpatients. Methods Post-hoc analysis of the clinical and psychopathological features associated with TEM among 91 BD-II depressed outpatients exposed to antidepressants. Results Second-generation antipsychotics (SGA) (p = .005), lithium (≤ .001), cyclothymic/irritable/hypert…

AdultMalemedicine.medical_specialtyBipolar DisorderAdolescentLithium (medication)media_common.quotation_subjectTreatment-emergent-maniaAntidepressantGastroenterologyYoung Adult03 medical and health sciencesBipolar Disorder (BD) Antidepressant Depression Treatment-emergent-mania0302 clinical medicineInternal medicineRecall biasOutpatientsmedicineHumansBipolar disorderAgedmedia_commonAntidepressant; Bipolar Disorder (BD); Depression; Treatment-emergent-mania; Clinical Psychology; Psychiatry and Mental Healthbusiness.industryDepressionMiddle Agedmedicine.diseaseBipolar Disorder (BD)Antidepressive Agents030227 psychiatryClinical PsychologyCross-Sectional StudiesTreatment OutcomeTolerabilityPsychiatry and Mental HealthAntidepressantDrug Therapy CombinationFemaleTemperamentmedicine.symptombusinessMania030217 neurology & neurosurgeryAntipsychotic AgentsPsychopathologymedicine.drug
researchProduct

Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observ…

2018

BACKGROUND: European guidelines recommend intravenous methylprednisolone as first-line treatment for active and severe Graves' orbitopathy; however, it is common for patients to have no response or have relapse after discontinuation of treatment. We aimed to compare the efficacy and safety of add-on mycophenolate to methylprednisolone in comparison with methylprednisolone alone in patients with moderate-to-severe Graves' orbitopathy.METHODS: MINGO was an observer-masked, multicentre, block-randomised, centre-stratified trial done in two centres in Germany and two in Italy. Patients with active moderate-to-severe Graves' orbitopathy were randomly assigned to receive intravenous methylprednis…

AdultMalemedicine.medical_specialtyCombination therapyAdolescentEndocrinology Diabetes and MetabolismPopulationMedizinAnti-Inflammatory Agents030209 endocrinology & metabolismMethylprednisoloneSeverity of Illness IndexMycophenolic acidlaw.inventionGraves' ophthalmopathy03 medical and health sciencesYoung Adult0302 clinical medicineEndocrinologyRandomized controlled trialDouble-Blind MethodlawInternal medicineJournal ArticleInternal MedicinemedicineHumanseducationAdverse effectAgededucation.field_of_studyAntibiotics Antineoplasticbusiness.industryMiddle AgedMycophenolic Acidmedicine.diseaseDiscontinuationGraves OphthalmopathyTreatment OutcomeMethylprednisoloneItaly030221 ophthalmology & optometryDrug Therapy CombinationFemalebusinessmedicine.drugThe lancet. Diabetesendocrinology
researchProduct

Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, gra…

1996

Differentiation induction therapy is being tested in myelodysplastic syndromes to ameliorate maturation defects and to restore normal hematopoietic function. To this end, 17 patients (eight with refractory anemia, two with refractory anemia and ring sideroblasts, and seven with refractory anemia and excess of blast cells) were treated with a combination of all-trans-retinoic acid (ATRA), granulocyte colony-stimulating factor (G-CSF), erythropoietin (EPO), and alpha-tocopherol for durations of 8-16 weeks. Absolute neutrophil counts increased in all patients; platelet counts increased in five patients with discontinuation of transfusion needs in two of four transfusion-dependent patients. Sti…

AdultMalemedicine.medical_specialtyCombination therapyTretinoinBone Marrowhemic and lymphatic diseasesInternal medicineGranulocyte Colony-Stimulating FactorMedicineHumansVitamin EErythropoietinAgedAged 80 and overHematologybusiness.industryMyelodysplastic syndromesHematologyGeneral MedicineMiddle Agedmedicine.diseaseGranulocyte colony-stimulating factorBlood Cell CountHematopoiesisHaematopoiesisEndocrinologymedicine.anatomical_structureErythropoietinMyelodysplastic SyndromesErythropoiesisDrug Therapy CombinationFemaleBone marrowbusinessmedicine.drugAnnals of hematology
researchProduct

Mycophenolate is effective in the treatment of pemphigus vulgaris.

1999

Background Pemphigus vulgaris is a potentially life-threatening autoimmune disease. Although combination therapies with prednisone and azathioprine are usually effective in controlling the disease, some patients either do not respond to this treatment or show early relapses. Objective To find out whether mycophenolate mofetil would be an effective drug in controlling pemphigus vulgaris in patients who failed initial treatment with azathioprine and prednisone. Results Twelve patients who were initially diagnosed as having pemphigus vulgaris and had relapsed while undergoing treatment with azathioprine (1.5-2 mg/kg of body weight) and prednisolone (2 mg/kg of body weight) subsequently receive…

AdultMalemedicine.medical_specialtyCombination therapymedicine.medical_treatmentPrednisoloneAzathioprineDermatologyMycophenolic acidPrednisoneAzathioprineMedicineHumansChemotherapybusiness.industryPemphigus vulgarisGeneral MedicineMiddle AgedMycophenolic Acidmedicine.diseaseDermatologyPemphigusTreatment OutcomeChemotherapy AdjuvantPrednisoloneDrug Therapy CombinationFemalebusinessImmunosuppressive AgentsPemphigusmedicine.drugArchives of dermatology
researchProduct

Factors associated with efficacy of an ibuprofen/pseudoephedrine combination drug in pharmacy customers with common cold symptoms

2016

SummaryAim The aim of this study was to explore factors affecting efficacy of treatment of common cold symptoms with an over-the-counter ibuprofen/pseudoephedrine combination product. Methods Data from an anonymous survey among 1770 pharmacy customers purchasing the combination product for treatment of own common cold symptoms underwent post-hoc descriptive analysis. Scores of symptoms typically responsive to ibuprofen (headache, pharyngeal pain, joint pain and fever), typically responsive to pseudoephedrine (congested nose, congested sinus and runny nose), considered non-specific (sneezing, fatigue, dry cough, cough with expectoration) and comprising all 11 symptoms were analysed. Multiple…

AdultMalemedicine.medical_specialtyCommon ColdInfectious DiseaseIbuprofenNonprescription DrugsPharmacy030226 pharmacology & pharmacyDrug Administration Schedule03 medical and health sciences0302 clinical medicineExpedited Clinical TrialSurveys and QuestionnairesInternal medicinemedicineHumans030223 otorhinolaryngologyNosePain Measurementbusiness.industryAnti-Inflammatory Agents Non-SteroidalCommon coldmultiple regression analysisGeneral MedicinePseudoephedrinemedicine.diseaseIbuprofenPseudoephedrinesymptom scoreNasal decongestantNasal DecongestantsTreatment Outcomemedicine.anatomical_structureAnesthesiaJoint painDrug Therapy CombinationFemalemedicine.symptombusinessmedicine.drugCombination drugInternational Journal of Clinical Practice
researchProduct

Treatment and its side effects in ANCA-associated vasculitides - Study based on POLVAS registry data.

2020

Abstract Purpose The aim of this study is to present the treatment modalities and associated side effects in a Polish nation-wide ANCA-associated vasculitides (AAV) patients’ cohort. Materials and methods Retrospective analysis of patients diagnosed with AAV between 1990 and 2016, included in the POLVAS registry was performed. Standard descriptive statistic methods were used with an emphasis on the treatment modalities. Results There were 625 patients diagnosed with AAV included in this study: 417 cases of granulomatosis with polyangiitis (GPA; 66.7%), 106 cases of microscopic polyangiitis (MPA; 17.0%) and 102 cases of eosinophilic granulomatosis with polyangiitis (EGPA; 16.3%). The mean ag…

AdultMalemedicine.medical_specialtyCyclophosphamideDrug-Related Side Effects and Adverse ReactionsAzathioprineAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis03 medical and health sciences0302 clinical medicineMaintenance therapyInternal medicineAzathioprinemedicineHumansTreatment complications030212 general & internal medicineRegistriesAdverse effectCyclophosphamideGlucocorticoidsANCA associated vasculitisRetrospective Studiesbusiness.industryVasculitis registryGeneral MedicineMiddle Agedmedicine.diseasePrognosisSurvival RateMethotrexate030220 oncology & carcinogenesisCohortRituximabDrug Therapy CombinationFemalePolandMicroscopic polyangiitisGranulomatosis with polyangiitisbusinessRituximabVasculitis treatmentImmunosuppressive Agentsmedicine.drugFollow-Up StudiesAdvances in medical sciences
researchProduct

The Addition of an Immunosuppressant After Loss of Response to Anti-TNFα Monotherapy in Inflammatory Bowel Disease: A 2-Year Study

2018

Background The addition of an immunosuppressant (IM) after loss of response to anti-TNFα monotherapy is an emerging strategy of therapeutic optimization in patients with inflammatory bowel disease (IBD). However, few clinical data have been reported to date. We aimed to evaluate the efficacy and safety of this selective combination therapy in patients with IBD. Methods All consecutive patients with loss of response to anti-TNFα monotherapy despite an intensive dose optimization who added an IM from October 2014 to October 2016 were entered into a prospective database. Results Among 630 patients treated with anti-TNFα agents during the study period, 46 (7.3%) added an IM. A total of 31 patie…

AdultMalemedicine.medical_specialtyDatabases FactualCombination therapyGastroenterologyInflammatory bowel diseaseDrug Administration Schedule03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdalimumabHumansImmunology and AllergyProspective StudiesAdverse effectbiologyTumor Necrosis Factor-alphabusiness.industryRemission InductionC-reactive proteinAdalimumabGastroenterologyAntibodies MonoclonalMiddle AgedInflammatory Bowel Diseasesmedicine.diseaseInfliximabGolimumabInfliximabDiscontinuationC-Reactive ProteinTreatment Outcome030220 oncology & carcinogenesisbiology.proteinDrug Therapy CombinationFemale030211 gastroenterology & hepatologybusinessImmunosuppressive Agentsmedicine.drugInflammatory Bowel Diseases
researchProduct